Samsung Biologics ^Corporation

Samsung Biologics was founded in April 2011 with a vision to become the most competitive Contract Development and Management Organization (CDMO) in the biopharmaceutical industry. The company was established by Samsung Electronics Co., Samsung Everland Inc., Samsung C&T Corp., and Quintiles Transnational Corp. Their headquarters are located in Incheon, South Korea, with plans to expand globally. Samsung holds fast to the Quality First principles on which it was founded. To that end, they strive to offer outstanding quality, innovation, and availability to their clients. This allows Samsung Biologics' partners to provide the most effective medicines to their end patients with cost savings and in the most efficient manner possible. To achieve their Quality First vision, Samsung has created a continual processing platform. This platform facilitates the manufacturing of biopharmaceutical products with the highest innovations in execution and quality. The advanced engineering used to build this process allows for both efficient production and absolute compliance with the vast number of global regulatory bodies involved in the creation of biopharmaceutical products. Samsung Biologics has a track record and reputation for excellence. These accolades extend to plant design, construction, operations, and execution. They strive to provide the highest quality and efficiency available in the CDMO biopharmaceutical space and have succeeded in offering their partners the means to create and distribute medicines, meeting the standards in the industry. The Samsung Biologics Quality Division oversees all operations and works strenuously to evaluate compliance with international regulatory and cGMP requirements. Their facilities are known for innovative engineering that brings products from inception and early-stage development all the way through the process until they meet the high standards necessary to enter the commercial supply chain. Samsung Biologics plans to continue the expansion of facilities and capabilities to meet the needs of the growing market. Dr. Tae Han Kim serves as the Chief Executive Officer of Samsung Biologics. Dr. Kim began his career with Samsung in 1979 and has been an integral member of senior leadership on several expansion projects, as well as leading the business and financial restructuring of Samsung General Chemicals. Dr. Kim holds a doctoral degree in chemical engineering.